BioRegenx Announces Board and Executive Changes
Ticker: BRGX · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1593184
| Field | Detail |
|---|---|
| Company | Bioregenx, INC. (BRGX) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
BioRegenx shakes up the board and exec comp. New faces, new pay.
AI Summary
BioRegenx, Inc. announced on January 15, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- BIOREGENX, INC. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- January 15, 2025 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates departures of certain officers and directors, but does not specify the exact roles in this summary section.
Who are the newly elected directors?
The filing mentions the election of new directors but does not list their names in the provided text.
What are the details of the new compensatory arrangements?
The filing notes adjustments to compensatory arrangements for certain officers but does not provide specific details in this section.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 15, 2025.
What is the principal executive office address for BioRegenx, Inc.?
The principal executive offices are located at 7407 Ziegler Road, Chattanooga, Tennessee 37421.
Filing Stats: 347 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-01-22 17:00:11
Filing Documents
- bioregenx_8k.htm (8-K) — 18KB
- 0001683168-25-000484.txt ( ) — 181KB
- fdit-20250115.xsd (EX-101.SCH) — 3KB
- fdit-20250115_lab.xml (EX-101.LAB) — 33KB
- fdit-20250115_pre.xml (EX-101.PRE) — 24KB
- bioregenx_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b). On January 15, 2025, Robert Doran submitted his resignation from his position as director of BioRegenx, Inc., which shall be effective January 31, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioRegenx, Inc. (Registrant) Date: January 22, 2025 By: /s/ William Resides Name: William Resides Title: Chief Executive Officer 2